Affymetrix, Inc.  

(Public, NASDAQ:AFFX)   Watch this stock  
Find more results for gene expression
Mar 31 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap 1.13B
P/E 117.22
Div/yield     -
EPS 0.12
Shares 80.54M
Beta     -
Inst. own 107%

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin 4.24% 2.81%
Operating margin 5.14% 4.64%
EBITD margin - 13.49%
Return on average assets 2.97% 1.96%
Return on average equity 4.84% 3.31%
Employees 1,150 -
CDP Score - -


3420 Central Expy
SANTA CLARA, CA 95051-0703
United States - Map
+1-408-7315000 (Phone)
+1-408-7315380 (Fax)

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha


Affymetrix, Inc. (Affymetrix) is a provider of life science products and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein and cell level. The Company operates through two business segments: Affymetrix Core and eBioscience. The Affymetrix Core segment focuses on the development, manufacture and commercialization of systems for genetic analysis in the life sciences, agricultural biotechnology (AgBio) and diagnostic industry. The eBioscience segment primarily focuses on the development, manufacture, marketing and distribution of research products in the areas of flow cytometry, immunoassays, microscopic imaging and other protein-based analyses. The Company sells its products to genomic research centers, academic institutions, government and private laboratories, as well as pharmaceutical, diagnostic and biotechnology companies. It maintains sales and distribution operations across the United States, Europe, Latin America and Asia.